Synonyms: ACP-044 | ACP044 | compound 1 [WO2020159643A1] [1]
Compound class:
Synthetic organic
Comment: The chemical structure for ebaresdax is claimed in Cersci Therapeutics' patent WO2020159643A1 [1], which allowed us to associate this structure with their clinical lead candidate ACP-044. This was confirmed by synonym matches on PubChem. Ebaresdax (ACP-044) is a first-in-class, orally administered, non-opioid analgesic that was developed for potential to treat neuropathic, surgical and osteoarthritic pain.
|
|
No information available. |
Summary of Clinical Use |
Ebaresdax (ACP-044) has progressed to phase 2 evaluations, for potential to reduce surgical and osteoarthritic pain. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05008835 | Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee | Phase 2 Interventional | ACADIA Pharmaceuticals Inc. | ||
NCT04855240 | Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy | Phase 2 Interventional | ACADIA Pharmaceuticals Inc. |